Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Ancobon (flucytosine) 250 mg and 500 mg Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2009

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.

 

Summary View

 

PRECAUTIONS

Pregnancy: Teratogenic Effects/ Pregnancy Category C

  •  Studies in pregnant rats have shown that fluocytosine injected intraperitoneally crosses the placental barrier.

ADVERSE REACTIONS

Gastrointestinal

  • including hepatic necrosis
  • enterocolitis

Hematologic

  • and fatal cases of bone marrow aplasia

 

-
-